Navigation Links
AAPS national biotechnology conference to highlight breakthrough cancer treatments
Date:5/12/2011

ARLINGTON, VA (May 3, 2011) Cancer studies from Mercer University (Ga.) headline groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). The conference takes place Monday, May 16 -Wednesday, May 18 at the Hilton San Francisco Union Square.

Developing an Oral Vaccine for Cervical Cancer

Cervical cancer is the second most common cancer among women in the world . Two preventative vaccines are currently available, but are expensive, require complex storage, and trained personnel to administer injections. A team at Mercer is seeking to change that by developing a nanoparticle based Human Papillomavirus (HPV) oral vaccine.

"The purpose of our study was to develop and test inexpensive HPV virus-like particulate vaccine formulations that can be administered orally much like a tablet or capsule," said Martin D'Souza, Ph.D., director of graduate programs and co-director of the Center for Drug Delivery and Research at Mercer. "If this technique is successful, vaccinations could be conducted in masses rather inexpensively and without the use of needles."

This research is currently in the formulation development phase and is being tested on an animal model. It is hoped that the study will help reduce the price of vaccine development for cervical cancer, helping make it more available to patients in poorer countries.

Promise Held for a Novel Combination Prostate Cancer Vaccine

Prostate cancer is the second-most common cancer among American men . The research team working on the HPV vaccine is also working on a prostate cancer vaccine that would be a combination of transdermal and oral administration.

"By using this vaccine we can assist the body's defenses to fight off the cancer," said D'Souza. "The vaccine also enables the body's immune cells to generate memory against these cancer cells, such that if [they] reemerge at a later stage, which is quite common, then the memory cells mount an immune response and destroy those cells as well."

Current studies in animal models showed that the vaccine delayed tumor growth, and that transdermal followed by oral vaccination produced a better response than transdermal vaccination alone. These particulate vaccines can be designed for individual therapy and aim to be more cost-effective since their production can be scaled up for mass vaccination due to the ease with which they are prepared.


'/>"/>

Contact: Joseph Catapano
catapanoj@aaps.org
703-248-4772
American Association of Pharmaceutical Scientists
Source:Eurekalert

Related biology news :

1. Consumption, carbon emissions and international trade
2. MU professor elected to membership in National Academy of Sciences
3. ASPB members elected to National Academy of Sciences
4. UCSF scientists honored by National Academy of Sciences
5. Louisiana Tech researcher presents on eco-friendly nanotechnology at national conference
6. Life in extreme environments paves the way for international collaboration
7. Engineering students win International Environmental Design Contest
8. Smell and taste experts at international conference -- April 13-17, 2011
9. 18th International Academy of Astronautics Humans in Space Symposium
10. National Biophotonic Sensors and Systems Center announced
11. ASPB member testifies in support of National Science Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: